The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Watch this short video to learn more about the International Psoriasis Council in less than a minute: Who we are, our vision, mission, history, and our community of psoriasis experts working to improve the health of people with psoriasis around the world.
The 2023 American Academy of Dermatology (AAD) Annual Meeting was held Thursday, March 16 – Tuesday, March 21, 2023, in New Orleans, LA, and is the largest dermatology meeting in the world, showcasing over 1,000 expert speakers and over 300 sessions. This report includes 13 summaries of talks focusing on psoriasis.
The European Commission has approved Sotyktu™ (deucravacitinib) in European Union.
The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.
In 2022, IFPA and IPC announced a new partnership to join their clinical expertise and the patient perspective. Here’s what they hope to achieve together.
The IPC global network has expanded! Please join us in welcoming our seven newest councilors.
IPC and IFPA strongly advocate that early diagnosis is crucial and must be available for all individuals regardless of race, ethnicity, physical ability, culture, nationality, or geographic location.
Amgen receives approval from the United States Food and Drug Administration (FDA) for AMJEVITA™, a biosimilar for adults with psoriasis and psoriatic arthritis.
The IPC Board of Directors is pleased to announce that it has named Bruce Strober, MD, PhD, as its newly appointed Vice President/President-Elect.
This announcement follows the September 2022 approval from the U.S. Food and Drug Administration (FDA) and the Japan’s Ministry of Health, Labour, and Welfare.
Craig Leonardi, MD, a Founder of the IPC, our immediate-past President, and a long-time Board Member, has accepted the position as an Honorary Founder.
